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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not pitolisant
is effective in reducing excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Study Design: Review of two randomized control trials (RCTs) published in 2013 and 2017, and
one prospective, placebo-controlled, single-blind study published in 2008.
Data Sources: All articles were published in English and taken from peer-reviewed journals,
which were found using the PubMed database.
Outcomes Measured: The outcomes of investigation measured include excessive daytime
sleepiness (EDS) assessed by change in Epworth Sleepiness Scale (ESS) score, and cataplexy
rate calculated from recorded cataplexy attacks in patients’ sleep diaries.
Results: Dauvilliers, et al. found pitolisant was more effective in reducing mean ESS scores
from baseline compared to placebo (-5.8 vs -3.4; p=0.024). A decrease in ESS score indicates
improved EDS. Also, in post-hoc analyses, Dauvilliers et al. found that pitolisant was superior to
placebo in reducing daily cataplexy rate from baseline (0.38 vs 0.92; p=0.034). Szakacs, et al.
found pitolisant to be effective in reducing weekly cataplexy rate (WCR) by 75% from baseline
compared to placebo (38% decrease in WCR), p <0.0001; they also report a significant decrease
in ESS score from baseline in the pitolisant group compared with placebo (-5.4 vs -1.9; p=
0.0001). In a single-blind, placebo-controlled, prospective study, Lin et al. found that tiprolisant
(currently called pitolisant) showed a significant reduction in ESS score from baseline compared
to placebo (5.9 vs 1.0; p<0.001).
Conclusions: Pitolisant was shown to be efficacious in reducing EDS and cataplexy in adults
with narcolepsy.
Key Words: Narcolepsy, pitolisant, tiprolisant
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INTRODUCTION
Narcolepsy is a rare, chronic neurological disorder characterized by excessive daytime
sleepiness (EDS) causing an individual to fall asleep at inappropriate times throughout the day,
which can disrupt work, school, and social life. According to DSM-5 criteria, EDS occurs at
least three times per week for at least three months with at least one of the following: cataplexy
(at least a few times per month), shortened rapid eye movement (REM) latency of ≤15 minutes
on polysomnography (or a multiple sleep latency test (MSLT) showing a mean sleep latency of
≤8 minutes and ≥2 sleep-onset REM periods), and hypocretin deficiency in CSF.1 Cataplexy is
defined as a sudden, brief loss of muscle tone associated with intense emotions (may have global
hypotonia without emotional triggers, which is seen in children or when onset of disease is
within six months), without loss of consciousness.
Narcolepsy usually presents in the teens or early twenties and has two peak onsets: ages
15-25 and 30-35 years.1 It affects 1 in 2,000 people in the US.2 Cataplexy often occurs within a
year in 50% of those diagnosed and affects 0.02 – 0.04% of the general population worldwide.1
Unfortunately, more than 80% of individuals with sleep disorders remain undiagnosed, which
costs the US economy over $400 billion per year in medical costs, decreased/lost productivity,
injuries, and screening programs.2 Literature reports a mean delay in diagnosis of narcolepsy of
up to 15 years, consequentially impacting the burden of disease.3 Individuals with narcolepsy
have a two to three-fold higher annual rate of inpatient admissions, and visits to the ED, hospital
outpatient centers, neurologist, pulmonologist, and PCP.4, 5 Studies have shown that the annual
average cost per patient for medical services and medications is more than double the amount for
patients with narcolepsy compared to matched controls ($11,702 vs $5261; p <0.0001).4
The exact etiology and pathogenesis of narcolepsy remain unclear, but a few causes have
been identified: genetics, decreases in hypocretin (orexin) neuropeptides, and destruction/loss of
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orexin neurons. Orexins are excitatory neuropeptides that project to histaminergic or
noradrenergic neurons known to play a key role in wakefulness.6 All patients with narcolepsy
suffer from EDS; other symptoms include abnormal REM sleep manifestations such as cataplexy
(most common and most debilitating), hallucinations and sleep paralysis, which intrude into their
wakefulness and vice versa, greatly impairing the person’s quality of life.2, 5
The usual method of treating narcolepsy combines lifestyle changes plus stimulants or
CNS depressants. Lifestyle changes include improving sleep hygiene by establishing a regular
sleep schedule, getting at least seven hours of sleep per night, taking short naps throughout the
day, daily exercise, and avoiding shift work. Psychostimulants such as modafinil,
methylphenidate, or amphetamine/dextroamphetamine are commonly used as wake-promoting
therapies to treat EDS.2, 7 CNS depressants such as sodium oxybate is currently the only drug that
is FDA approved for both cataplexy and EDS in adults.7, 8 Antidepressants such as SSRIs,
SNRIs, and TCAs are used off-label for cataplexy, however supporting evidence is scarce.7
Narcolepsy is a lifelong, debilitating disorder with no cure currently available. EDS and
cataplexy are the two most commonly reported symptoms and known to significantly impact
daily living. Since only one drug is FDA approved to treat both EDS and cataplexy, some
patients must manage their symptoms with multiple medications. Sodium oxybate, while
effective at treating both EDS and cataplexy, can however cause serious adverse effects and
requires an inconvenient nightly dosing administration, in which the patient needs to set an alarm
2.5 to 4 hours later to take the second dose. Thus, a need exists for more safe and convenient
drugs that can treat both EDS and cataplexy. Studies have shown that histamine neurons play a
significant role in maintaining wakefulness9 and patients with the most severe loss of orexin
neurons tend to show the highest increase in histaminergic neurons in narcolepsy,10 providing a
targeted area of study in which to activate histaminergic transmissions for arousal. Research
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demonstrates H1 and H3 histamine receptors in the brain are important in mediating the wakepromoting effects of histamine.9 Studies suggest pitolisant, a histamine H3-receptor inverse
agonist, activates these histaminergic neurons to release histamine and in turn increase
wakefulness, thereby treating EDS and cataplexy in adults with narcolepsy. This review
evaluates two randomized controlled trials (RCTs) and a prospective, single-blind, placebocontrolled trial comparing the efficacy of pitolisant in reducing EDS and cataplexy in adult
patients with narcolepsy.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not pitolisant is
effective in reducing excessive daytime sleepiness and cataplexy in adults with narcolepsy.
METHODS
All selected articles were published in English, in peer-reviewed journals, and found on
the PubMed database using the following search terms: “Narcolepsy”, “pitolisant”, and
“tiprolisant.” Articles were selected based on relevance to the stated clinical question and
whether or not the outcomes mattered to patients. The inclusion criteria were placebo-controlled,
single or double-blind primary resource studies, with at least two being RCTs, published no more
than 10 years ago. Studies with patients younger than 18 years of age and initial/baseline ESS
scores of less than 10 were excluded. Statistics reported in this review include mean change
from baseline, confidence intervals, p-values, relative benefit increase (RBI), relative risk
reduction (RRR), absolute risk reduction (ARR), absolute benefit increase (ABI), and numbers
needed to treat (NNT). Demographics and characteristics of each study are provided in Table 1.
This review examines two double-blind, placebo-controlled RCTs and one prospective,
sequential placebo-controlled, single-blind trial. The patient population selected for this review
included individuals at least 18 years of age diagnosed with narcolepsy with or without
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cataplexy. The intervention under study was pitolisant (formerly called tiprolisant and BF2.649),
a selective histamine H3 receptor inverse agonist. Comparisons were made against a control
group receiving a placebo. Outcomes measured were patient oriented and included EDS
(assessed by Epworth Sleepiness Scale (ESS) score) and cataplexy rate based on those reported
in patients’ sleep dairies.
Table 1: Demographics and Characteristics of included studies
Study

Type

#
Pts

Dauvilliers
(2013)11

Double-blind,
placebocontrolled,
parallel-group
RCT

95

Szakacs
(2017)12

Lin
(2008)13

Double-blind,
placebocontrolled
RCT

Pilot,
prospective,
comparative,
sequential
placebocontrolled,
single-blind

106

22

Age
(yrs)
≥18

≥18

≥28

Inclusion Criteria
● Pts ≥18yo with
narcolepsy
+/- cataplexy, no
psychostimulants for
≥14 days
● have EDS
(ESS score ≥14)
● Self-reported EDS
for >3mo
● Narcolepsy
confirmed by
polysomnogram
● multiple sleep
latency test (MSLT)
within 5yrs – mean
sleep latency (MSL)
of ≤ 8min with ≥2
REM periods
● Pts ≥18yo with
narcolepsy with
cataplexy (≥3/wk)
● have EDS (ESS
score ≥12)
● Narcolepsy
confirmed by
polysomnogram
● MSLT within 1yr
and ≥2 REM periods

● Adults with
narcolepsy with
cataplexy
● EDS with 2≤
direct onset REM
periods and a MSL
<8mins during an
MSLT

Exclusion
Criteria
● Use of IND
within 30 days
before screening
● any disorder
(d/o) that could
cause EDS in
those without
cataplexy
● history of
substance abuse,
CVD, liver or
renal
abnormalities, or
psych disorders

W/D

Interventions

1

Pitolisant
(10mg, 20mg,
or 40mg/day),
4 cap, po once
daily in AM x
8wks

● Use of any
psychostimulant
or sedative meds
● Participation in
another trial
within a month
before screening
● History of any
other d/o with
EDS, substance
abuse, CVD,
liver/renal
abnormalities, or
a psych d/o
● ESS score <10

1

(3wks flexible
dosing followed
by 5wks stable
dosing)

Pitolisant
(5mg, 10 mg,
20 mg, or
40mg), 1cap
po once daily
in AM
x 7wks
(3wks flexible
dosing followed
by 4wks stable
dosing)

0

Tiprolisant
40mg, 1 cap
po once daily
in AM x
1week
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OUTCOMES MEASURED
The outcomes measured were change in EDS and cataplexy rate with pitolisant versus
placebo. In all three articles, EDS was assessed by change in mean ESS score from baseline.11-13
The ESS is a self-administered questionnaire that subjectively measures and screens for EDS by
assessing the chance of falling asleep in eight ordinary life situations. Each item on the scale is
graded from 0 – 3; thus, the score can range from 0 (normal, with no chance of falling sleep) to a
max of 24 (severe EDS). A decrease in ESS score indicates improved EDS and an ESS score of
10 or lower is considered normal.14 Dauvilliers et al. and Szakacs et al. also gave additional posthoc analysis and secondary endpoint analysis, respectively, of dichotomous data on ESS
responder rates, defined as patients with a final ESS (ESSf) score of 10 or lower.11, 12 Cataplexy
rates were calculated from the mean number of attacks reported in patients’ individual sleep
diaries. Szakacs et al. and Dauvilliers et al. report weekly and daily (defined as ≥1 cataplexy
attacks during baseline or treatment period) cataplexy rate reduction from baseline, respectively,
as the ratio of final weekly cataplexy rate divided by the corresponding baseline (WCRf/b). In a
secondary analysis, Szakacs et al. also gave dichotomous data on the proportion of patients who
had a weekly cataplexy rate (WCR) >15 at the end of the treatment study.12 The post-hoc and
secondary assessments were completed in order to confirm differences between the pitolisant and
placebo groups.
RESULTS
All three studies used in this review aim to demonstrate the efficacy of pitolisant on EDS
and/or number of cataplexy attacks by verifying whether the results of pitolisant are superior to
those of placebo. Two double-blinded RCTs assessed both reduction of EDS and cataplexy,
while one single-blinded trial assessed only reduction in EDS. All studies consisted of
participants from multiple sleep centers in Europe. The inclusion and exclusion criteria of all
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three articles are comparable (Table 1), and all patients who received at least one study dose
were included in the intention-to-treat analysis. Prior to baseline (preceding randomization)
patients discontinued psychostimulants, but were permitted to continue anticataplectic agents
(sodium oxybate or antidepressants, except TCAs due to effect on H1 receptors in the brain and
drug interactions with pitolisant) throughout the trial. In each of the studies, change in arithmetic
mean ESS score was calculated. To test the superiority of pitolisant over placebo, they then
adjusted for baseline values to show treatment effect between the groups.
In Dauvilliers et al.11 95 patients were randomly assigned to treatment: 30 to placebo, 32
to pitolisant, and 33 to modafinil. However, comparisons with modafinil are not included in this
EBM review. One patient was lost from the pitolisant group due to withdrawal of consent (before
receiving any treatment), leaving 94 patients in the intention-to-treat analysis, and 57 (61%) of
which who had cataplexy. Double-blinding was maintained throughout the eight-week treatment
phase and all patients were given four capsules per day, matched to placebo in taste and
appearance, despite their assigned treatment or dose. The treatment period consisted of 3 weeks
of flexible dosing (10mg, 20mg, or 40mg/day of pitolisant adjusted for individual clinical
efficacy and safety) followed by 5 weeks of stable, assigned dosing.11 Change in mean ESS score
from baseline was the primary analysis of this study. They found pitolisant was more effective in
reducing mean ESS scores from baseline compared to placebo (-5.8 vs -3.4; p=0.024; table 2).
In a double-blinded, RCT conducted by Szakacs et al.,12 106 patients with cataplexy were
randomly assigned to treatment: 54 to pitolisant and 52 to placebo. One patient was lost from the
placebo group due to injury unrelated to the trial; since they never received a dose they were not
included in the intention-to-treat analysis. The treatment phase lasted 7 weeks: 3 weeks of
flexible dosing (5mg, 10mg, or 20mg/day of pitolisant) followed by 4 weeks of stable, assigned
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dosing (5mg, 10mg, 20mg, or 40mg pitolisant). Change in mean WCR from baseline was the
principle outcome of this study.
Lin et al.13 conducted a pilot, prospective, single-blinded two-week study of 22 patients
(21 with cataplexy), all whom were included in the intention-to-treat analysis. Without knowing
the sequence, patients were given 1 week of placebo followed by 1 week of a fixed dose of
tiprolisant 40mg/day. Unlike the other two trials, each participant acted as their own control. The
principle outcome of this study was change in mean ESS score from baseline (Table 2).
P-values of less than 0.05 indicate that there is a less than 5% chance that improvement in
ESS scores occurred by chance and that there is a statistically significant difference in change in
ESS score from baseline compared to placebo. The researchers used continuous data to present
these findings, which is provided in Table 2. Despite change in ESS scores being negative or
positive, all values indicate reduction of points from baseline. In each study reviewed, patients
given pitolisant had a greater reduction in mean change of ESS score from baseline compared to
placebo, indicating statistically significant improvement (reduction) in EDS.
Table 2: Comparison of change in mean ESS score from baseline compared to placebo
Study
Dauvilliers, et al. 11
Szakacs, et al. 12
Lin, et al. 13

Pitolisant
-5.8 (SD 6.2)
-5.4
5.9 (SD 5.5)

Placebo
-3.4 (SD 4.2)
-1.9
1.0 (SD 4.9)

Treatment effect (95% CI)
-3.0 (-5.6 to -0.4)
-3.48 (-5.03 to -1.92)
4.9 (2.22 to 7.56)

P-Value
0.024
0.0001
0.0006

In the two double-blinded RCTs11,12 additional dichotomous data on the percentage of
ESS responders (defined as patients with final ESS scores (ESSf) ≤ 10 after the treatment study)
were used to further determine efficacy of pitolisant. An ESS score of ≤ 10 is considered within
normal range. In a post-hoc analysis conducted by Dauvilliers et al.11 45% (14/31 patients) of
patients given pitolisant have reported an ESSf ≤10, compared to 13% (4/30 patients) of those
given placebo (p<0.0006, 95% CI: 4.4 (2.1–9.2)). Similarly, in a secondary efficacy assessment
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conducted by Szakacs et al.12 39% (20/51 patients) of patients given pitolisant reported an ESSf
≤10, compared to 18% (9/50 patients) given placebo (p = 0.035, 95% CI: 3.28 (1.08–9.92)).
Determining the numbers needed to treat (NNT) value establishes clinical significance of the
intervention. The NNT values of 3 and 5 mean that for every 3 or 5 patients with narcolepsy
treated with pitolisant, one more patient will report an ESSf ≤ 10 (improved EDS) compared to
those receiving a placebo (Table 3).
Table 3: Comparison of ESS responders (final ESS ≤ 10) between pitolisant and placebo
Study

Dauvilliers,
et al. 11
Szakacs, et
al. 12

Control
Event Rate
(CER)
0.13

Experimental
event rate
(EER)
0.45

Relative
benefit
increase (RBI)
2.46

Absolute
benefit
increase (ABI)
0.32

Number
needed to
treat (NNT)
3

P-Value

0.18

0.39

1.17

0.21

5

0.035

<0.0006

In the RCT conducted by Szakacs et al.12 the primary outcome was change in geometric
mean of WCR from baseline, which is reported as the ratio of final weekly cataplexy rate divided
by the corresponding baseline (WCRf/b). These results are recorded as continuous data and
provided in Table 4. This study found pitolisant to be effective in reducing WCR by 75%
(WCRf/b = 0.25) from baseline compared to placebo (38% decrease in WCR, WCRf/b = 0.62, p
<0.0001, Table 4). The p-value listed in Table 4 indicates that WCR was reduced significantly
with pitolisant compared to placebo.
Table 4: Change in mean WCR from baseline of the Szakacs, et al.12 RCT
Treatment

Baseline

Final

Pitolisant (n=54)
Placebo (n=51)

9.15
7.31

2.27
4.52

Change
(Final/Baseline)
0.25
0.62

Treatment effect
(95% CI)
0.51 (0.43–0.60)

P-Value
< 0.0001

Dauvilliers et al.11 gave additional post-hoc analysis on the change in geometric mean of
daily cataplexy rate from baseline. These results are recorded as continuous data and provided in
Table 5 below. This analysis included only the patients who reported in their sleep diaries at least
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one cataplexy attack during baseline or during the 8-week treatment phase. Pitolisant reduced
daily cataplexy rate by 62% (0.38) from baseline versus 8% in those taking placebo (0.92).
Pitolisant was effective and superior to placebo in reducing mean cataplexy rate from baseline
(p= 0.034, Table 5).
Table 5: Change in mean daily cataplexy rate from baseline of the Dauvilliers, et al.11 RCT
Treatment
Pitolisant (n=20)
Placebo (n=14)

Baseline
(SD)
0.52 (0.6)
0.43 (0.7)

Final
(SD)
0.18 (0.4)
0.39 (0.6)

Change
(Final/Baseline)
0.38
0.92

Treatment effect
(95% CI)
0.38 (0.16–0.93)

P-Value
0.034

Szakacs et al.12 conducted a secondary analysis on the proportion of patients with a final
WCR greater than 15. This dichotomous data showed 7% (4/54 patients) of patients given
pitolisant reported a final WCR >15, compared to 24% (12/51 patients) of those given placebo.
The percentage of patients reporting high cataplexy rate was significantly decreased with
pitolisant versus placebo, with p-value = 0.005. The NNT value of -6 means that for every 6
patients with narcolepsy and cataplexy treated with pitolisant, one less patient will report
severely high WCR (WCR>15) compared to those taking placebo (Table 6).
Table 6: Proportion of patients with final WCR >15 between pitolisant and placebo
Study
Szakacs, et al.12

Control
Event Rate
(CER)
0.24

Experimental
event rate
(EER)
0.07

Relative risk
reduction
(RRR)
- 0.71

Absolute risk
reduction
(ARR)
- 0.17

Number
needed to
treat (NNT)
-6

P-Value

0.005

DISCUSSION
Pitolisant (formerly tiprolisant and BF2.649) is a selective histamine H3-receptor inverse
agonist that inhibits H3-autoreceptors, activating histaminergic neurons in the brain to release
histamine and thereby promote wakefulness.9,13 It is not yet FDA approved and therefore not
currently available in the US. Pitolisant (brand name Wakix, in EU) was approved by the EMA
(European Medicines Agency) in 2016 and available for use in some countries in Europe only
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for the treatment of adults with narcolepsy with or without cataplexy.9,15 At this moment,
pitolisant is not used for anything else other than to treat EDS and cataplexy in adults with
narcolepsy. Pitolisant is well tolerated, with minor adverse effects such as: headaches (most
common), nausea, insomnia, anxiety, and irritability.11-13 The contraindications of pitolisant
include: pregnancy, severe allergic reaction to pitolisant, and severe hepatic impairment (ChildPugh class C).16 No known black box warnings exist at this time. Pitolisant was shown to be
effective in reducing EDS and cataplexy with once daily dosing in the morning.
Since pitolisant is a new drug of its class, and the first H3-receptor inverse agonist to be
utilized in clinical trials with patients, the availability of completed primary research is scarce,
rendering limited search results for this review. Regarding limitations of the studies themselves,
all three articles consisted of a short duration of treatment, which may hinder pitolisant from
reaching its maximum effectiveness and not allow assessment of tolerance of the drug. Another
potential limitation in all three trials is that they took place in Europe, where their standards and
regulations may be different from those followed in the US. Also, exclusion of children or those
younger than 18 years old, patients with severe comorbidities, and those refusing placebo limit
the ability to generalize findings to these populations.
The phase II study by Lin et al13 was the first clinical trial done on this drug class.
Limitations of this study included: a short-term duration of two weeks, a small sample size of 22
patients, single-blinding, and fixed dosing. The small sample size may not be indicative of the
population at large. Giving each patient the same dose (40mg tiprolisant) may not have allowed
for individual efficacy of the drug. Also, with the trial being single-blinded and sequentially
placebo-controlled, this could have invited bias into the analysis of results and patient response
to treatment.
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CONCLUSION
After reviewing the data of all three articles and despite the limitations previously
mentioned, it is conclusive that pitolisant is an effective treatment to significantly reduce both
EDS and cataplexy in adults with narcolepsy.11-13 Each study in this review was limited to
narcoleptic patients in Europe, warranting future study to evaluate the effects of pitolisant on
EDS and cataplexy on adults with narcolepsy in the US. Ongoing studies include assessing longterm evaluation of safety and efficacy of pitolisant in narcoleptic patients.17 Also, the studies
included in this review do not use DSM-5 criteria to define their inclusion/exclusion criteria, thus
they did not consider the orexin levels in CSF, which is now an important diagnostic feature of
those with narcolepsy with cataplexy. Thus, these results must be analyzed carefully because of
possible bias in their selection of patients. Therefore, future research should diagnose according
to DSM-5 and include its criteria in their inclusion/exclusion process. Furthermore, patients with
narcolepsy often times complain of decreased attention and memory. H3-receptors and histamine
are known to play a key role in learning and memory.18,19 Further research should determine the
efficacy of pitolisant on improvement of attention and memory in patients with narcolepsy.
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